{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:59:43Z","timestamp":1792403983056,"version":"4.4.0"},"reference-count":188,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Antibody\u2013drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deliver drugs to tumor cells while minimizing toxicity to normal tissue, achieving wider therapeutic windows and enhanced pharmacokinetic\/pharmacodynamic properties. To date, nine ADCs have been approved by the FDA and more than 80 ADCs are under clinical development worldwide. In this paper, we provide an overview of the biology and chemistry of each component of ADC design. We briefly discuss the clinical experience with approved ADCs and the various pathways involved in ADC resistance. We conclude with perspectives about the future development of the next generations of ADCs, including the role of molecular imaging in drug development.<\/jats:p>","DOI":"10.3390\/molecules25204764","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T08:14:50Z","timestamp":1602922490000},"page":"4764","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":389,"title":["Antibody\u2013Drug Conjugates for Cancer Therapy"],"prefix":"10.3390","volume":"25","author":[{"given":"Umbreen","family":"Hafeez","sequence":"first","affiliation":[{"name":"Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, VIC 3084, Australia"},{"name":"Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, VIC 3084, Australia"},{"name":"School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3891-2489","authenticated-orcid":false,"given":"Sagun","family":"Parakh","sequence":"additional","affiliation":[{"name":"Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, VIC 3084, Australia"},{"name":"Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, VIC 3084, Australia"},{"name":"School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui K.","family":"Gan","sequence":"additional","affiliation":[{"name":"Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, VIC 3084, Australia"},{"name":"Department of Medical Oncology, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, VIC 3084, Australia"},{"name":"School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia"},{"name":"Department of Medicine, University of Melbourne, Melbourne, VIC 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Scott","sequence":"additional","affiliation":[{"name":"Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, VIC 3084, Australia"},{"name":"School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia"},{"name":"Department of Medicine, University of Melbourne, Melbourne, VIC 3084, Australia"},{"name":"Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC 3084, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"ref_1","unstructured":"Factsheet, W. (2019, November 29). Cancer. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"j4530","DOI":"10.1136\/bmj.j4530","article-title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: Retrospective cohort study of drug approvals 2009\u201313","volume":"359","author":"Davis","year":"2017","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-Drug Conjugates in Cancer Therapy","volume":"64","author":"Sievers","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"ref_5","unstructured":"Sharma, V. (2020, July 07). CPhI Annual Report 2018: ADCs Growth Driven by Lack of In-House Facilities, Oncology and Integrated CDMOs. Available online: https:\/\/www.pharmoutsourcing.com\/Featured-Articles\/354437-CPhI-Annual-Report-2018-ADCs-Growth-Driven-by-Lack-of-In-House-Facilities-Oncology-and-Integrated-CDMOs\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody\u2013drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2015.04.002","article-title":"Mechanisms of action of therapeutic antibodies for cancer","volume":"67","author":"Redman","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.coph.2018.05.010","article-title":"Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases","volume":"41","author":"Hafeez","year":"2018","journal-title":"Curr. Opin. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1158\/1535-7163.MCT-06-0026","article-title":"Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin\/p97","volume":"5","author":"Smith","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.drudis.2013.11.004","article-title":"Antibody-drug conjugates: Current status and future directions","volume":"19","author":"Perez","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","article-title":"HER2: Biology, detection, and clinical implications","volume":"135","author":"Gutierrez","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2007.06883.x","article-title":"High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate","volume":"140","author":"Ingle","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4161\/mabs.22854","article-title":"Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates","volume":"5","author":"Ritchie","year":"2013","journal-title":"mAbs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"mAbs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1158\/1078-0432.CCR-05-0204","article-title":"Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys","volume":"11","author":"Sapra","year":"2005","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-11-1417","article-title":"Antibody conjugate therapeutics: Challenges and potential","volume":"17","author":"Teicher","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrd3270","article-title":"Antibody-drug conjugates for cancer: Poised to deliver?","volume":"9","author":"Hughes","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-Drug Conjugates: A Comprehensive Review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: The neonatal Fc receptor comes of age","volume":"7","author":"Derry","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: From structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/nbt1207-1369","article-title":"Isotype selection in antibody engineering","volume":"25","author":"Jochen","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4161\/mabs.2.3.11788","article-title":"Stability of IgG isotypes in serum","volume":"2","author":"Correia","year":"2010","journal-title":"mAbs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF02899970","article-title":"The immunoglobulin hinge (Interdomain) region","volume":"6","author":"Adlersberg","year":"1976","journal-title":"Ric. Clin. E Lab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/pro.3598","article-title":"A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress","volume":"28","author":"Saito","year":"2019","journal-title":"Protein Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1395127","DOI":"10.1080\/2162402X.2017.1395127","article-title":"Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)","volume":"7","author":"Hoffmann","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1158\/1078-0432.CCR-17-3786","article-title":"Mechanistic Insights of an Immunological Adverse Event Induced by an Anti-KIT Antibody Drug Conjugate and Mitigation Strategies","volume":"24","author":"Orozco","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wang, Y.-J., Li, Y.-Y., Liu, X.-Y., Lu, X.-L., Cao, X., and Jiao, B.-H. (2017). Marine Antibody-Drug Conjugates: Design Strategies and Research Progress. Mar. Drugs, 15.","DOI":"10.3390\/md15010018"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Yasunaga, M., Manabe, S., Tsuji, A., Furuta, M., Ogata, K., Koga, Y., Saga, T., and Matsumura, Y. (2017). Development of Antibody-Drug Conjugates Using DDS and Molecular Imaging. Bioengineering, 4.","DOI":"10.3390\/bioengineering4030078"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab Emtansine for HER2-positive advanced breast cancer. (Clinical report)","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_30","first-page":"3912","article-title":"Targeting, internalization, and cytotoxicity of methotrexate-monoclonal anti-stage-specific embryonic antigen-1 antibody conjugates in cultured F-9 teratocarcinoma cells","volume":"46","author":"Shen","year":"1986","journal-title":"Cancer Res."},{"key":"ref_31","first-page":"3118","article-title":"Antitumor xenograft activity with a conjugate of a Vinca derivative and the squamous carcinoma-reactive monoclonal antibody PF1\/D","volume":"47","author":"Johnson","year":"1987","journal-title":"Cancer Res."},{"key":"ref_32","first-page":"6097","article-title":"Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug","volume":"48","author":"Dillman","year":"1988","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1200\/JCO.1999.17.2.478","article-title":"Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients with Metastatic Breast Cancer","volume":"17","author":"Tolcher","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cbpa.2009.03.023","article-title":"Potent antibody drug conjugates for cancer therapy","volume":"13","author":"Senter","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_35","unstructured":"Wellcome Sanger Institute (2020, July 13). Genomics of Drug Sensitivity in Cancer. Available online: https:\/\/www.cancerrxgene.org\/compound\/Mitomycin-C\/136\/overview\/ic50."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/mp500781a","article-title":"Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody\u2013Drug Conjugate SYD985","volume":"12","author":"Elgersma","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: A phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Mantaj, J., Jackson, P.J.M., Karu, K., Rahman, K.M., and Thurston, D.E. (2016). Covalent Bonding of Pyrrolobenzodiazepines (PBDs) to Terminal Guanine Residues within Duplex and Hairpin DNA Fragments. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0152303"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/med.20212","article-title":"Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines","volume":"32","author":"Gerratana","year":"2012","journal-title":"Med. Res. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1158\/1078-0432.CCR-19-0711","article-title":"A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody\u2013drug conjugate, in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"25","author":"Kahl","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s40265-015-0489-4","article-title":"Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products","volume":"75","author":"Trendowski","year":"2015","journal-title":"Drugs"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Chen, H., Lin, Z., Arnst, K.E., Miller, D.D., and Li, W. (2017). Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy. Molecules, 22.","DOI":"10.3390\/molecules22081281"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody\u2013Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Satpayev","year":"2016","journal-title":"Cancer Res."},{"key":"ref_50","unstructured":"AbbVie News Center (2019). AbbVie Provides Update on Depatuxizumab Mafodotin Depatux-M, An Investigational Medicine for Newly Diagnosed Glioblastoma, an Aggressive Form of Brain Cancer, AbbVie News Center."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1021\/ja00759a054","article-title":"Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus","volume":"94","author":"Kupchan","year":"1972","journal-title":"J. Am. Chem. Soc."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-10-0644","article-title":"Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules","volume":"9","author":"Lopus","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1200\/JCO.2013.54.8115","article-title":"Phase I\/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients with Advanced Melanoma","volume":"32","author":"Ott","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1158\/1078-0432.CCR-14-0012","article-title":"FDA approval: Ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer","volume":"20","author":"Blumenthal","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1177\/00912700122012751","article-title":"Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse","volume":"41","author":"Dowell","year":"2001","journal-title":"J. Clin. Pharm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/bc010021y","article-title":"Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/bloodadvances.2018026211","article-title":"Inotuzumab: From preclinical development to success in B-cell acute lymphoblastic leukemia","volume":"3","author":"Wynne","year":"2019","journal-title":"Blood Adv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/1878-0261.12600","article-title":"TR1801-ADC: A highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors","volume":"14","author":"Gymnopoulos","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/cbf.1149","article-title":"The role of glutathione in cancer","volume":"22","author":"Balendiran","year":"2004","journal-title":"Cell Biochem. Funct."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/fon-2017-0379","article-title":"A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","article-title":"Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing","volume":"66","author":"Erickson","year":"2006","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: Mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.drup.2014.11.001","article-title":"Antibody-targeted drugs and drug resistance\u2014Challenges and solutions","volume":"18","author":"Benhar","year":"2015","journal-title":"Drug Resist. Updates"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1021\/acs.molpharmaceut.5b00082","article-title":"Antibody Conjugates with Unnatural Amino Acids","volume":"12","author":"Hallam","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jim.2007.12.011","article-title":"Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs","volume":"332","author":"Junutula","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/nprot.2012.045","article-title":"Site-specific chemical protein conjugation using genetically encoded aldehyde tags","volume":"7","author":"David","year":"2012","journal-title":"Nat. Protoc."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1039\/b908687k","article-title":"Site specific protein labeling by enzymatic posttranslational modification","volume":"7","author":"Sunbul","year":"2009","journal-title":"Org. Biomol. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/2472555220912955","article-title":"Advances in Antibody\u2013Drug Conjugate Design: Current Clinical Landscape and Future Innovations","volume":"25","author":"Sassoon","year":"2020","journal-title":"SLAS Discov. Adv. Sci. Drug Discov."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nature01451","article-title":"Regulated portals of entry into the cell","volume":"422","author":"Sean","year":"2003","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2147\/DDDT.S135571","article-title":"Intracellular trafficking of new anticancer therapeutics: Antibody-drug conjugates","volume":"11","author":"Kalim","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13046-017-0667-1","article-title":"Fate of Antibody-Drug Conjugates in Cancer Cells","volume":"37","author":"Chalouni","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required?","volume":"117","author":"Alexander","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40259-018-0302-5","article-title":"Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody\u2013Drug Conjugates","volume":"32","author":"Khera","year":"2018","journal-title":"BioDrugs"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bph.13697","article-title":"Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells","volume":"174","author":"Fuh","year":"2017","journal-title":"Br. J. Pharm."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2013-05-505685","article-title":"A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies","volume":"122","author":"Deckert","year":"2013","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_81","first-page":"2277","article-title":"Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: Results of a systematic review and meta-analysis of prospective studies","volume":"9","author":"Chen","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: A highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3109\/10428194.2012.676170","article-title":"Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin","volume":"53","author":"Bartlett","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40268-014-0036-x","article-title":"Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: A case report","volume":"14","author":"Urru","year":"2014","journal-title":"Drugs R&D"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2009.26.2071","article-title":"Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer","volume":"28","author":"Krop","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial","volume":"18","author":"Krop","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: Results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_92","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): A randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients with Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody\u2013drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1021\/acs.molpharmaceut.8b00225","article-title":"Metabolism of an Oxime-Linked Antibody Drug Conjugate, AGS62P1, and Characterization of its Identified Metabolite","volume":"15","author":"Snyder","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.2020.38.15_suppl.1039","article-title":"A phase I dose escalation study evaluating the safety and tolerability of a novel anti-HER2 antibody-drug conjugate (PF-06804103) in patients with HER2-positive solid tumors","volume":"38","author":"Calvo","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1200\/JCO.2018.36.15_suppl.5565","article-title":"PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study","volume":"36","author":"Sachdev","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1158\/1535-7163.MCT-19-0219","article-title":"Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors","volume":"19","author":"Akla","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"P6-7-13","DOI":"10.1158\/1538-7445.SABCS18-P6-17-13","article-title":"Abstract P6-17-13: ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers","volume":"79","author":"Hamblett","year":"2019","journal-title":"Cancer Res."},{"key":"ref_106","unstructured":"Hamilton, E.B.M., Tolcher, A., Buscema, J., Papadopoulos, K.P., Zarwan, C., Anderson, C., and Doroshow, D. (2020). Mersana Therapeutics Reports Updated Interim Data from the Ovarian Cancer Cohort of the XMT-1536 Phase 1 Expansion Study, News Bites Pty Ltd."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1470-2045(19)30830-7","article-title":"San Antonio Breast Cancer Symposium 2019","volume":"21","author":"Gourd","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"P6-20-16","DOI":"10.1158\/1538-7445.SABCS18-P6-20-16","article-title":"Abstract P6-20-16: BAT8003, a potent anti-Trop-2 antibody-drug conjugate, for the treatment of triple negative breast cancer","volume":"79","author":"Tang","year":"2019","journal-title":"Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1200\/JCO.2020.38.4_suppl.713","article-title":"Phase Ia, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic, or biliary cancers","volume":"38","author":"Ko","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/19420862.2019.1618674","article-title":"Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity","volume":"11","author":"Shen","year":"2019","journal-title":"mAbs"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10637-018-0570-4","article-title":"Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: A dose-escalation, phase I study","volume":"36","author":"Stathis","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/jco.2011.29.15_suppl.8013","article-title":"Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed\/refractory multiple myeloma (MM)","volume":"29","author":"Berdeja","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cllc.2016.09.002","article-title":"Phase 1\/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin\/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease","volume":"18","author":"Socinski","year":"2017","journal-title":"Clin. Lung. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"556","DOI":"10.4161\/mabs.27756","article-title":"Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models","volume":"6","author":"Whiteman","year":"2014","journal-title":"mAbs"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1093\/annonc\/mdy048.004","article-title":"A Phase 1a\/2a trial of AVID100, an anti-EGFR antibody-drug conjugate","volume":"29","author":"Tolcher","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1158\/1535-7163.MCT-18-0624","article-title":"MEN1309\/OBT076, a First-In-Class Antibody\u2013Drug Conjugate Targeting CD205 in Solid Tumors","volume":"18","author":"Merlino","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.clml.2019.02.006","article-title":"Indatuximab Ravtansine (BT062) Monotherapy in Patients with Relapsed and\/or Refractory Multiple Myeloma","volume":"19","author":"Jagannath","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","article-title":"The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo","volume":"15","author":"Ikeda","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"v140","DOI":"10.1093\/annonc\/mdx367.055","article-title":"PROCLAIM-CX-2009: A first-in-human trial to evaluate CX-2009 in adults with metastatic or locally advanced unresectable solid tumors","volume":"28","author":"Spira","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"9072","DOI":"10.1200\/JCO.2019.37.15_suppl.9072","article-title":"First-in-human phase 1 study of the antibody-drug conjugate (ADC) SAR408701 in advanced solid tumors: Dose-expansion cohort of patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC)","volume":"37","author":"Gazzah","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1200\/JCO.2017.35.15_suppl.5547","article-title":"Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts","volume":"35","author":"Moore","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"LB-291","DOI":"10.1158\/1538-7445.AM2013-LB-291","article-title":"Abstract LB-291: First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors","volume":"73","author":"Bendell","year":"2013","journal-title":"Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody\u2013Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1158\/1538-7445.AM2018-820","article-title":"Abstract 820: Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer","volume":"78","author":"Scribner","year":"2018","journal-title":"Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"PD1-03","DOI":"10.1158\/1538-7445.SABCS18-PD1-03","article-title":"Abstract PD1-03: Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results of a phase 1\/2 trial","volume":"79","author":"Masuda","year":"2019","journal-title":"Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5181","DOI":"10.1158\/1538-7445.AM2020-5181","article-title":"Abstract 5181: Therapeutic targeting of GPR20, selectively expressed in gastrointestinal stromal tumor (GIST), with DS-6157a, an antibody-drug conjugate (ADC)","volume":"80","author":"Iida","year":"2020","journal-title":"Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"9051","DOI":"10.1200\/JCO.2019.37.15_suppl.9051","article-title":"First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors","volume":"37","author":"Sands","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1158\/1535-7163.MCT-17-1215","article-title":"MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FR\u03b1 Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity","volume":"17","author":"Cheng","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood-2018-99-112955","article-title":"A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed\/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies","volume":"132","author":"Daver","year":"2018","journal-title":"Blood"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/1538-7445.AM2018-832","article-title":"Abstract 832: An AXL-specific antibody-drug conjugate shows preclinical anti-tumor activity in non-small cell lung cancer, including EGFR-inhibitor resistant NSCLC","volume":"78","author":"Koopman","year":"2018","journal-title":"Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"TPS12126","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS12126","article-title":"A phase 1\/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors","volume":"36","author":"Ahnert","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2020.38.15_suppl.3502","article-title":"CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer","volume":"38","author":"Johnson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"TPS3652","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3652","article-title":"SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors","volume":"38","author":"Patnaik","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"S1805","DOI":"10.1016\/j.jtho.2017.09.458","article-title":"Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC","volume":"12","author":"Goldman","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"PD4-06","DOI":"10.1158\/1538-7445.SABCS19-PD4-06","article-title":"Abstract PD4-06: Early clinical development of RC48-ADC in patients with HER2 positive metastatic breast cancer","volume":"80","author":"Xu","year":"2020","journal-title":"Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.toxlet.2019.12.027","article-title":"Preclinical safety profile of disitamab vedotin: A novel anti-HER2 antibody conjugated with MMAE","volume":"324","author":"Jiang","year":"2020","journal-title":"Toxicol. Lett."},{"key":"ref_137","unstructured":"Alteogen Secures (2018). FDA Approval for Orphan Drug Designation with An Antibody-Drug Conjugate for Gastric Cancer. Health & Beauty Close-Up, Alteogen Inc."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"TPS1101","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS1101","article-title":"First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed\/refractory solid tumors","volume":"38","author":"Li","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_139","unstructured":"OBI Pharma, Inc. (2018). Press Release: OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer, OBI Pharma, Inc."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2019-126827","article-title":"Vls-101 is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter\u2019s Syndrome (RS)","volume":"134","author":"Vaisitti","year":"2019","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"PD1-06-PD01-06","DOI":"10.1158\/1538-7445.SABCS19-PD1-06","article-title":"Abstract PD1-06: Open label phase 1b\/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer","volume":"80","author":"Han","year":"2020","journal-title":"Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): A first-in-human, multicentre, phase 1\u20132 trial","volume":"20","author":"Concin","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-19-1004","article-title":"ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers","volume":"19","author":"Skidmore","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"B005","DOI":"10.1158\/1535-7163.TARG-19-B005","article-title":"Abstract B005: A phase I study of A166, a novel anti-HER2 antibody-drug conjugate (ADC), in patients with locally advanced\/metastatic solid tumors","volume":"18","author":"Lopez","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1158\/1538-7445.AM2018-835","article-title":"Abstract 835: TRPH-222, a novel anti-CD22 antibody drug conjugate (ADC), has significant anti-tumor activity in NHL xenografts and reduces B cells in monkeys","volume":"78","author":"Maclaren","year":"2018","journal-title":"Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood-2018-99-116081","article-title":"Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"132","author":"Radford","year":"2018","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood-2018-99-118198","article-title":"Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed\/Refractory Classical Hodgkin Lymphoma","volume":"132","author":"Hamadani","year":"2018","journal-title":"Blood"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Anderson, M.G., Falls, H.D., Mitten, M.J., Oleksijew, A., Vaidya, K.S., Boghaert, E.R., Gao, W., Palma, J.P., Cao, D., and Chia, P.-L. (2020). Targeting Multiple EGFR Expressing Tumors with a Highly Potent Tumor-Selective Antibody Drug Conjugate. Mol. Cancer Ther.","DOI":"10.1158\/1535-7163.MCT-20-0149"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"B120","DOI":"10.1158\/1535-7163.TARG-17-B120","article-title":"Abstract B120: TAK-164, a GCC-targeted antibody-drug conjugate (ADC) for the treatment of colorectal cancers and other GI malignancies","volume":"17","author":"Bannerman","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1182\/blood-2019-122754","article-title":"Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies","volume":"134","author":"Shah","year":"2019","journal-title":"Blood"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1158\/1538-7445.AM2018-1782","article-title":"Abstract 1782: Discovery and activity of STRO-002, a novel ADC targeting folate receptor alpha for ovarian and endometrial cancer","volume":"78","author":"Li","year":"2018","journal-title":"Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41401-018-0198-0","article-title":"SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models","volume":"40","author":"Yang","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-17-3671","article-title":"Resistance to Antibody-Drug Conjugates","volume":"78","author":"Pandiella","year":"2018","journal-title":"Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor Cells Chronically Treated with a Trastuzumab\u2013Maytansinoid Antibody\u2013Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/cup.12797","article-title":"Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: A novel finding","volume":"43","author":"Patel","year":"2016","journal-title":"J. Cutan. Pathol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1158\/1078-0432.CCR-13-0358","article-title":"Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: Critical role for neuregulin blockade in antitumor response to combination therapy","volume":"20","author":"Phillips","year":"2014","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","article-title":"Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)","volume":"17","author":"Sung","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity","volume":"77","author":"Arribas","year":"2017","journal-title":"Cancer Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1158\/1078-0432.CCR-18-1300","article-title":"SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads","volume":"24","author":"Kinneer","year":"2018","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Collins, D.M., Bossenmaier, B., Kollmorgen, G., and Niederfellner, G. (2019). Acquired Resistance to Antibody-Drug Conjugates. Cancers, 11.","DOI":"10.3390\/cancers11030394"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.exphem.2009.03.002","article-title":"Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML","volume":"37","author":"Haag","year":"2009","journal-title":"Exp. Hematol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood-2003-11-3825","article-title":"The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin","volume":"103","author":"Walter","year":"2004","journal-title":"Blood"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","article-title":"Mechanisms of Resistance to Antibody\u2013Drug Conjugates","volume":"15","author":"Loganzo","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/0008-5472.CAN-09-3546","article-title":"Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance","volume":"70","author":"Kovtun","year":"2010","journal-title":"Cancer Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/clpt.2010.286","article-title":"Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000\u20132009","volume":"89","author":"Kaitin","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/mde.1360","article-title":"The cost of biopharmaceutical R&D: Is biotech different?","volume":"28","author":"DiMasi","year":"2007","journal-title":"Manag. Decis. Econ."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"938","DOI":"10.7150\/thno.37443","article-title":"Monoclonal antibody-based molecular imaging strategies and theranostic opportunities","volume":"10","author":"Dammes","year":"2020","journal-title":"Theranostics"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1536012118801223","DOI":"10.1177\/1536012118801223","article-title":"Application of Immuno-PET in Antibody\u2013Drug Conjugate Development","volume":"17","author":"Carmon","year":"2018","journal-title":"Mol. Imaging"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1634\/theoncologist.12-12-1379","article-title":"Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications","volume":"12","author":"Visser","year":"2007","journal-title":"Oncologist"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","article-title":"ImmunoPET: Concept, Design, and Applications","volume":"120","author":"Wei","year":"2020","journal-title":"Chem. Rev."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1021\/acs.molpharmaceut.7b01168","article-title":"Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models","volume":"15","author":"Kang","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/1878-0261.12166","article-title":"A novel enediyne-integrated antibody\u2013drug conjugate shows promising antitumor efficacy against CD30+ lymphomas","volume":"12","author":"Wang","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2019.02.002","article-title":"Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma","volume":"448","author":"Wang","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1080\/21691401.2019.1709857","article-title":"Preliminary biological evaluation of 123I-labelled anti-CD30-LDM in CD30-positive lymphomas murine models","volume":"48","author":"Gong","year":"2020","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ijc.1450","article-title":"TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence","volume":"94","author":"Harper","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"14523","DOI":"10.1073\/pnas.96.25.14523","article-title":"STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors","volume":"96","author":"Hubert","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"25103","DOI":"10.18632\/oncotarget.8390","article-title":"ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1","volume":"7","author":"Williams","year":"2016","journal-title":"Oncotarget"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/1078-0432.CCR-15-1272","article-title":"ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment","volume":"22","author":"Lamberts","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1021\/acs.molpharmaceut.8b00275","article-title":"Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates","volume":"15","author":"Azhdarinia","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41416-018-0118-6","article-title":"Targeting LGR5 in Colorectal Cancer: Therapeutic gold or too plastic?","volume":"118","author":"Morgan","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/1535-7163.MCT-16-0114","article-title":"LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence","volume":"15","author":"Gong","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_184","first-page":"3254","article-title":"Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors","volume":"60","author":"Scott","year":"2000","journal-title":"Cancer Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1158\/1078-0432.CCR-04-0037","article-title":"Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-Acetyl gamma calicheamicin dimethyl hydrazide targets lewisy and eliminates Lewis(y)-positive human carcinoma cells and xenografts","volume":"10","author":"Boghaert","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"6709","DOI":"10.1158\/1078-0432.CCR-09-0536","article-title":"Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers","volume":"15","author":"Herbertson","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1158\/1078-0432.CCR-07-0284","article-title":"A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen","volume":"13","author":"Scott","year":"2007","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/annonc\/mdv577","article-title":"Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): The ZEPHIR trial","volume":"27","author":"Gebhart","year":"2016","journal-title":"Ann. Oncol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/20\/4764\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:22:54Z","timestamp":1760178174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/20\/4764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":188,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["molecules25204764"],"URL":"https:\/\/doi.org\/10.3390\/molecules25204764","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]}}}